Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
Go back to Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform| (NASDAQ: NTLA) | Delayed: 11.21 +0.05 (0.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.16 | 52 Week High | $30.40 | |||
| Open | $11.00 | 52 Week Low | $11.86 | |||
| Day High | $11.24 | P/E | N/A | |||
| Day Low | $10.58 | EPS | $0.00 | |||
| Volume | 3,564,678 | |||||



